IL180817A0 - Specific inhibition of autoimmunity and diseases associated with autoantigens - Google Patents
Specific inhibition of autoimmunity and diseases associated with autoantigensInfo
- Publication number
- IL180817A0 IL180817A0 IL180817A IL18081707A IL180817A0 IL 180817 A0 IL180817 A0 IL 180817A0 IL 180817 A IL180817 A IL 180817A IL 18081707 A IL18081707 A IL 18081707A IL 180817 A0 IL180817 A0 IL 180817A0
- Authority
- IL
- Israel
- Prior art keywords
- autoantigens
- autoimmunity
- diseases associated
- specific inhibition
- inhibition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/55—Vectors comprising a special translation-regulating system from bacteria
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Cardiology (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US58970704P | 2004-07-20 | 2004-07-20 | |
| US61452904P | 2004-09-29 | 2004-09-29 | |
| PCT/US2005/025878 WO2006012416A2 (en) | 2004-07-20 | 2005-07-20 | Specific inhibition of autoimmunity and diseases associated with autoantigens |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL180817A0 true IL180817A0 (en) | 2007-06-03 |
Family
ID=35786697
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL180817A IL180817A0 (en) | 2004-07-20 | 2007-01-18 | Specific inhibition of autoimmunity and diseases associated with autoantigens |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20090053249A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1778296B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2008507282A (cg-RX-API-DMAC7.html) |
| CN (1) | CN101068574B (cg-RX-API-DMAC7.html) |
| CA (1) | CA2574802A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL180817A0 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2006012416A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1616016B1 (en) * | 2003-03-19 | 2012-11-14 | Isogenis, Inc. | Gene therapy vectors having reduced immunogenicity based on cd8 alpha-chain |
| EP2020240A1 (en) * | 2007-07-30 | 2009-02-04 | Paul-Ehrlich-Institut Bundesamt für Sera und Impfstoffe | Methods and substances for the treatment of Alzheimer's |
| EP2342321B1 (en) * | 2008-09-17 | 2018-04-11 | Isogenis, Inc. | Construction of fully-deleted adenovirus-based gene delivery vectors and uses thereof |
| US9850296B2 (en) | 2010-08-10 | 2017-12-26 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
| AU2011289579B2 (en) * | 2010-08-10 | 2016-11-17 | Ecole Polytechnique Federale De Lausanne | Erythrocyte-binding therapeutics |
| US9848587B2 (en) * | 2013-02-20 | 2017-12-26 | Regeneron Pharmaceuticals, Inc. | Humanized T cell co-receptor mice |
| KR102181336B1 (ko) | 2013-06-13 | 2020-11-24 | 오르제네시스 엘티디. | 세포 집단, 이의 전환분화 방법 및 이용 방법 |
| US20160158352A1 (en) * | 2013-07-10 | 2016-06-09 | The United States of America, as represented by the Secretary, Department of Health & Human Servic | Apoptotic cell-mediated induction of antigen specific regulatory t-cells for the therapy of autoimmune diseases in animals and humans |
| CN106456744A (zh) | 2014-04-01 | 2017-02-22 | 鲁比厄斯治疗法股份有限公司 | 用于免疫调节的方法和组合物 |
| US11123404B2 (en) | 2016-01-07 | 2021-09-21 | B. G. Negev Technologies And Applications Ltd., At Ben-Gurion University | Methods for generating immunotolerant responses |
| WO2018207179A1 (en) | 2017-05-08 | 2018-11-15 | Orgenesis Ltd. | Transdifferentiated cell populations and methods of use thereof |
| AU2018338786A1 (en) * | 2017-09-29 | 2020-04-16 | Nantcell, Inc. | Antigenic proteins and methods therefor |
| US12583894B2 (en) * | 2018-04-04 | 2026-03-24 | University Of Florida Research Foundation, Incorporated | Materials and methods for the treatment of Lewy body disorders |
| AU2019256536C1 (en) | 2018-04-19 | 2026-01-15 | Baylor College Of Medicine | Reprogramming CD4 T cells into cytotoxic CD8 cells by forced expression of CD8αβ and Class 1 restricted T cell receptors |
| US12234473B2 (en) | 2020-12-31 | 2025-02-25 | Immatics US, Inc. | CD8 polypeptides, compositions, and methods of using thereof |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5078998A (en) * | 1985-08-02 | 1992-01-07 | Bevan Michael J | Hybrid ligand directed to activation of cytotoxic effector T lymphocytes and target associated antigen |
| US6048729A (en) * | 1987-05-01 | 2000-04-11 | Transkaryotic Therapies, Inc. | In vivo protein production and delivery system for gene therapy |
| US5242687A (en) * | 1989-03-15 | 1993-09-07 | Tkb Associates Limited Partnership | Method of reducing cellular immune response involving T-cells using CD8-bearing antigen presenting cells |
| JPH04506061A (ja) * | 1989-03-15 | 1992-10-22 | タイコシンスキー,マーク エル. | Cd8に基づく製剤 |
| US5601828A (en) * | 1989-03-15 | 1997-02-11 | Tkb Associates Limited Partnership | CD8 derivatives and methods of use for cellular modulation and enhancement of cellular engraftment |
| US5672346A (en) | 1992-07-27 | 1997-09-30 | Indiana University Foundation | Human stem cell compositions and methods |
| US5540926A (en) * | 1992-09-04 | 1996-07-30 | Bristol-Myers Squibb Company | Soluble and its use in B cell stimulation |
| ES2072223B1 (es) | 1993-11-25 | 1996-03-16 | Lipotec Sa | Liposomas encapsulando doxorubicina. |
| US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
| US5851806A (en) * | 1994-06-10 | 1998-12-22 | Genvec, Inc. | Complementary adenoviral systems and cell lines |
| US6143292A (en) | 1995-05-25 | 2000-11-07 | Baxter International Inc. | Allogeneic cell therapy for cancer following allogeneic stem cell transplantation |
| IL115199A (en) * | 1995-09-07 | 2005-05-17 | Opperbas Holding Bv | Composition comprising a polynucleic acid molecule in a liposome and method using said composition |
| GB9524973D0 (en) * | 1995-12-06 | 1996-02-07 | Lynxvale Ltd | Viral vectors |
| US5939250A (en) | 1995-12-07 | 1999-08-17 | Diversa Corporation | Production of enzymes having desired activities by mutagenesis |
| US5830696A (en) | 1996-12-05 | 1998-11-03 | Diversa Corporation | Directed evolution of thermophilic enzymes |
| US5965408A (en) | 1996-07-09 | 1999-10-12 | Diversa Corporation | Method of DNA reassembly by interrupting synthesis |
| WO1997025446A1 (en) * | 1996-01-05 | 1997-07-17 | Genetic Therapy, Inc. | Recombinase-mediated generation of adenoviral vectors |
| US6734014B1 (en) | 1996-02-08 | 2004-05-11 | The United States Of America As Represented By The Department Of Health And Human Services | Methods and compositions for transforming dendritic cells and activating T cells |
| US5952221A (en) | 1996-03-06 | 1999-09-14 | Avigen, Inc. | Adeno-associated virus vectors comprising a first and second nucleic acid sequence |
| US6228646B1 (en) | 1996-03-07 | 2001-05-08 | The Regents Of The University Of California | Helper-free, totally defective adenovirus for gene therapy |
| US6060054A (en) * | 1996-04-10 | 2000-05-09 | National Jewish Medical And Research Center | Product for T lymphocyte immunosuppression |
| US5763239A (en) | 1996-06-18 | 1998-06-09 | Diversa Corporation | Production and use of normalized DNA libraries |
| US6211342B1 (en) | 1996-07-18 | 2001-04-03 | Children's Hospital Medical Center | Multivalent MHC complex peptide fusion protein complex for stimulating specific T cell function |
| BR9713498A (pt) * | 1996-11-08 | 2000-02-29 | Idec Pharma Corp | Identificação de interações de ligação singulares entre alguns anticorpos e os antìgenos co-estimulatórios b7.1 e b7.2 humanos |
| US5873458A (en) | 1997-09-12 | 1999-02-23 | Kao; Kuo-Min | Drawer type CD box structure |
| GB9722779D0 (en) * | 1997-10-28 | 1997-12-24 | Isis Innovation | Human CD8 as an inhibitor of the cellular immune system |
| EP1025242A1 (en) * | 1997-10-30 | 2000-08-09 | Cornell Research Foundation, Inc. | A method of inhibiting an immune response to a recombinant vector |
| AU3456099A (en) | 1998-03-31 | 1999-10-18 | Geron Corporation | Methods and compositions for eliciting an immune response to a telomerase antigen |
| US5945325A (en) | 1998-04-20 | 1999-08-31 | California Institute Of Technology | Thermally stable para-nitrobenzyl esterases |
| US20020127205A1 (en) * | 1998-08-31 | 2002-09-12 | Albert Edge | Cells expressing immunoregulatory molecules and uses therefor |
| US6509150B1 (en) * | 1999-03-05 | 2003-01-21 | Universite De Nantes | Compositions and methods for recombinant Adeno-Associated Virus production |
| GB9906177D0 (en) | 1999-03-17 | 1999-05-12 | Oxford Biomedica Ltd | Anti-viral vectors |
| JP2002541845A (ja) * | 1999-04-16 | 2002-12-10 | セルテック セラピューティックス リミテッド | 合成膜貫通成分 |
| US6544506B2 (en) * | 2000-01-05 | 2003-04-08 | Yeda Research & Development Co. Ltd. | Veto cells effective in preventing graft rejection and devoid of graft versus host potential |
| US6762031B2 (en) | 2000-06-16 | 2004-07-13 | University Of Medicine And Dentistry Of New Jersey | Targeting viral vectors to specific cells |
| US6534052B1 (en) | 2000-09-05 | 2003-03-18 | Yong-Fu Xiao | Cardiac function comprising implantation of embryonic stem cell in which differentiation has been initiated |
| WO2002022212A2 (en) * | 2000-09-18 | 2002-03-21 | Idec Pharmaceuticals Corporation | Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination |
| US7235358B2 (en) * | 2001-06-08 | 2007-06-26 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing and monitoring transplant rejection |
| US7026121B1 (en) * | 2001-06-08 | 2006-04-11 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing and monitoring transplant rejection |
| GB0114533D0 (en) | 2001-06-14 | 2001-08-08 | Avidex Ltd | Substances |
| EP1616016B1 (en) * | 2003-03-19 | 2012-11-14 | Isogenis, Inc. | Gene therapy vectors having reduced immunogenicity based on cd8 alpha-chain |
| US9701019B2 (en) | 2011-09-15 | 2017-07-11 | Convergent Information Technologies Gmbh | System and method for the automatic generation of robot programs |
| ES2741897T3 (es) | 2012-02-13 | 2020-02-12 | Radius Eng Inc | Cartucho reutilizable para moldeo por inyección |
-
2005
- 2005-07-20 CA CA002574802A patent/CA2574802A1/en not_active Abandoned
- 2005-07-20 EP EP05790332A patent/EP1778296B1/en not_active Expired - Lifetime
- 2005-07-20 JP JP2007522752A patent/JP2008507282A/ja active Pending
- 2005-07-20 CN CN2005800317082A patent/CN101068574B/zh not_active Expired - Fee Related
- 2005-07-20 WO PCT/US2005/025878 patent/WO2006012416A2/en not_active Ceased
- 2005-07-20 US US11/572,259 patent/US20090053249A1/en not_active Abandoned
-
2007
- 2007-01-18 IL IL180817A patent/IL180817A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1778296A2 (en) | 2007-05-02 |
| WO2006012416A3 (en) | 2006-07-20 |
| US20090053249A1 (en) | 2009-02-26 |
| EP1778296A4 (en) | 2008-12-17 |
| CN101068574B (zh) | 2012-07-18 |
| CN101068574A (zh) | 2007-11-07 |
| EP1778296B1 (en) | 2012-06-06 |
| JP2008507282A (ja) | 2008-03-13 |
| CA2574802A1 (en) | 2006-02-02 |
| WO2006012416A2 (en) | 2006-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL183458A0 (en) | Anti-il-1r1 single domain antibodies and therapeutic uses | |
| IL182734A0 (en) | 4-aminotetracyclines and methods of use thereof | |
| EP1843768A4 (en) | SUBSTITUTED MORPHINANES AND METHODS OF USE | |
| IL178593A (en) | Specific antibodies of fcγriib and methods for their use | |
| IL177193A0 (en) | Anti-cd3 and antigen -specific immunotherapy to treat autoimmunity | |
| IL182498A0 (en) | Therapeutic furopyrimidines and thienopyrimidines | |
| IL199045A0 (en) | Antagonist anti-notch3 antibodies and their use in the prevention and treatment of notch3-related diseases | |
| IL176958A0 (en) | Compounds and methods of use | |
| IL181054A0 (en) | Ceramide derivatives as modulators of immunity and autoimmunity | |
| PL2056845T3 (pl) | Struktura i zastosowanie oligonukleotydów z 5'-fosforanem | |
| EP1827391A4 (en) | DOSAGE FORMS AND METHODS OF USE THEREOF | |
| IL179140A0 (en) | Antibody drug conjuates and methods | |
| IL181670A0 (en) | Substituted phenylaminothiazoles and use thereof | |
| EP1778296A4 (en) | SPECIFIC INHIBITION OF AUTOIMMUNITY AND DISEASES ASSOCIATED WITH AUTO-ATIGENING | |
| PT1711070E (pt) | Composição nutricional para melhorar o estado da pele e prevenir doenças de pele | |
| EP1789047A4 (en) | PROCESS FOR TREATING DISEASES USING NALMEFENE AND ITS ANALOGUES | |
| PT2380573E (pt) | Acetato de eslicarbazepina e métodos de utilização | |
| EP1733045A4 (en) | DESIGN AND THERAPEUTIC USE OF ADPASE-ENHANCED APYRASES | |
| EP1790574A4 (en) | CLADDING FOR A HYGIENIC CIGARETTE BOX AND SANITARY CIGARETTE BOX | |
| EP1838288A4 (en) | THERAPEUTIC MATERIALS AND METHODS | |
| ZA200705080B (en) | Aminocarboxylic acid derivative and medicinal use thereof | |
| EP1885381A4 (en) | PHARMACEUTICAL USE OF GRAPTOPETALUM AND RELATED PLANTS | |
| GB0407382D0 (en) | Therapeutic methods and means | |
| IL179555A0 (en) | Indentification of ergothioneine transporter and therapeutic uses thereof | |
| IL178970A0 (en) | Haplotype markers and methods of using the same to determine response to treatment |